ABVX:EPA
Abivax SA
78,50 €
arrow_downward
-0,76%(-0,60) 1K
16-noy, 11:15:16 (GMT+1) · EUR
search
Barcha belgilar
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoABVX tikeri uchun statistika yaratilmoqda...
Ochish
79,00 €
Yuqori
79,75 €
Past
78,15 €
Bozor kapitali
6,87 mlrd
Oʻrtacha hajm
109,70 ming
Hajmi
6,30 ming
52 haftalik eng yuqori
139,00 €
52 haftalik eng past
60,45 €
Aksiya boʻyicha daromad
-5,20 €
Muomaladagi aksiyalar
87,55 mln
Xodimlar soni
98
Ochish
79,00 €
Yuqori
79,75 €
Past
78,15 €
Bozor kapitali
6,87 mlrd
Oʻrtacha hajm
109,70 ming
Hajmi
6,30 ming
52 haftalik eng yuqori
139,00 €
52 haftalik eng past
60,45 €
Aksiya boʻyicha daromad
-5,20 €
Muomaladagi aksiyalar
87,55 mln
Xodimlar soni
98
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Idéal Investisseur
·
2 kun oldin
Abivax shares among the biggest decliners in the SBF 120, down 27.5% over three months
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA haqida
CEOMarc de Garidel | Hartmut J. Ehrlich
Xodimlar soni98
Asos solingan4-dek, 2013
Bosh ofislar-
SektorHealth Care
Soha-
Veb-saytabivax.com